PEPTIDE CORTEXThe library
← The library

CagriSema

researchMetabolic/Weight
Evidence grade
DResearch/compounded/adjunct (no established FDA indication)
Cardiovascular · 0–5 · separate axis
2
Read first · not dosing instructions

Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.

PurposeMetabolic / Weight
MechanismFixed-dose combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist)
EffectsCombines two established mechanisms; among the most-watched obesity candidates
DosingTrial doses (not approved): REDEFINE 1 started at 0.25 mg of each drug and increased every 4 weeks to cagrilintide 2.4 mg + semaglutide 2.4 mg once weekly by week 16, then 52 weeks of maintenance.
Bottom linePopular in research/compounding; human safety/benefit not well-established.
Protocols · as published3 sourced
Clinical trialREDEFINE 1 (NEJM 2025)
RouteSubcutaneous injection
FrequencyOnce weekly, 68 weeks
Starting0.25 mg of each drug
EscalationIncreased every 4 weeks until 2.4 mg of each drug was reached by week 16; investigators could delay escalation or reduce the dose for adverse effects
TargetCagrilintide 2.4 mg + semaglutide 2.4 mg once weekly, 52-week maintenance. Weight change -20.4% (treatment-policy) vs -3.0% placebo.

Only 57.4% of the CagriSema group were on 2.4/2.4 mg at week 68. Not FDA-approved.

Clinical trialREDEFINE 2, type 2 diabetes (NEJM 2025)
RouteSubcutaneous injection
FrequencyOnce weekly, 68 weeks
StartingNot given in the summary
EscalationNot given in the summary
TargetCagriSema 2.4/2.4 mg weekly. Weight change -15.7% vs -3.1% placebo.

From a search-result summary; the paper was not read directly.

Community protocol — not clinically establishedCommunity guide
RouteSubcutaneous injection
FrequencyOnce weekly
Starting0.25 mg of each component weekly
Escalation0.25/0.25 weeks 1-4, 0.5/0.5 weeks 5-8, 1.0/1.0 weeks 9-12, 1.7/1.7 weeks 13-16, 2.4/2.4 mg from week 17. The intermediate steps are the guide's; the NEJM text says only "increased every 4 weeks".
TargetCagrilintide 2.4 mg + semaglutide 2.4 mg weekly
Cycle"Standard research cycle: 12-24 weeks" (no trial basis); trial-mirroring 68 weeks
Batches on filenone

No tested batches on file.

Read with10
Cautions & interactions

Not FDA-approved; avoid self-administration; unverified sourcing and purity

No well-established interaction profile for non-approved peptides; avoid combining multiple research compounds; discuss meds with clinician.

CV 2 of 5 — Semaglutide has cardiovascular outcomes data on its own; the combination does not yet.